Weekly Round Up

A New Era for DNA-Based Medicine

Ambulatory Surgery Centers (ASCs) are becoming a more important part of U.S. healthcare delivery

Healthcare M&A Is Shrinking. Who’s Still Buying?

R&D Spending Surges as Sleep Tech Heats Up

Pharma R&D Spending Rises, Rouge Tx Advances, and Sleep Tech Scales

A Hepatitis B Breakthrough, Merck’s $1B Bet

FDA approval for potential Hepatitis B cure, Biomedical Engineering scaling fast, and Merck's $1B acquisition

The Cyber Problem Holding Back AI

AI’s Cybersecurity Problem, Estuary Bio, and the Oncology Pharma Power Map

FDA Shifts Rare Disease Rules as Biotech M&A Heats Up

Rare Disease Biotech Could Get a New Risk Profile

$42B → $82B: healthcare staffing doubles

Plus: why 59% of health systems are moving past cost-cutting.

Tariffs Changed the MedTech Playbook

Pharma’s $130B M&A Comeback, China’s Innovation Rise, Healthcare’s Third-Party Risk

Biopharma dealmaking is accelerating as drug innovation goes global—and China closes the gap with the U.S.

Lilly’s $3.35B China Bet, Healthcare M&A’s Bottleneck, Biotech’s New Pipeline

Plus: once-weekly insulin, $120B in China-linked licensing deals, and the risks slowing healthcare M&A.

Hospitals’ Next Margin Lever, AI’s Trust Gap, Healthcare M&A

Labor productivity takes center stage, 60% of consumers are already using AI for health, and big-ticket healthcare deals remain missing.

Europe’s Pharma Warning, Apollo’s Healthcare Play & China’s $60B Biotech Boom

Europe fights to keep biotech capital as Apollo consolidates healthcare media and China becomes a global pharma pipeline.